Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | President, Worldwide R&D | September 13, 2024 | September 17, 2024 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 20, 2023 | January 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date September 13, 2024 · Filed September 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 185,074 |
Ending reported balance
After 2024-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-30 · Grant · Acquired 300 · Balance 197,172 F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan. Row 2 · 2024-09-13 · Tax withholding · Disposed 12,098 · Balance 185,074 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
Mirati Therapeutics, Inc.
Report date January 20, 2023 · Filed January 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,465 |
Reported balance
After 2023-01-20 transaction · row 1
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 4,444 · Balance 10,465 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.66 · Expires 2033-01-20 | Direct | 7,520 |
Reported balance
After 2023-01-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-20 · Grant · Acquired 7,520 · Balance 7,520 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 6,878 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.01 · Expires 2026-06-12 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,399 | $232.01 | $324,575.83 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,383 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $231.70 to $232.625. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,218 | $230.19 | $280,368.38 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,782 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $229.63 to $230.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 17:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 10,000 | $20.54 | $205,400.00 |
DisclosureSEC source: 0001214659-20-010487 · marketforms-50648.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionNon Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $20.54 | $0.00 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · derivative · entry 8 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2024-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 500 | $133.07 | $66,536.00 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 7 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $133.04 to $133.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 5,800 | $132.34 | $767,567.94 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 6 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $132.03 to $132.885. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,300 | $131.08 | $170,407.51 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 5 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $130.86 to $131.835. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 1,000 | $129.80 | $129,803.00 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $129.66 to $130.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 900 | $128.56 | $115,706.97 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,600 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $128.04 to $128.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | SaleCommon Stock | 500 | $127.52 | $63,762.00 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $126.98 to $127.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 17:36 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Exercise / conversionCommon Stock | 10,000 | $20.54 | $205,400.00 |
DisclosureSEC source: 0001214659-20-006974 · marketforms-49432.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 11, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 49,423 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · derivative · entry 7 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,423 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 75,716 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · derivative · entry 6 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,716 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 1,250 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · derivative · entry 5 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 126,389 | $130.00 | $16,430,570.00 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,995 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.04. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 49,423 | $63.10 | $3,118,591.30 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,384 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 75,716 | $67.81 | $5,134,301.96 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 21:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 1,250 | $67.81 | $84,762.50 |
DisclosureSEC source: 0001567619-20-013577 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 8,977 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · derivative · entry 8 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,423 Underlying: Common Stock · 8,977 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 13,810 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · derivative · entry 7 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,716 Underlying: Common Stock · 13,810 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 224 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · derivative · entry 6 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 224 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 23,011 | $130.00 | $2,991,430.00 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · nonDerivative · entry 5 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,995 F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $130.00 to $130.025. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,977 | $63.10 | $566,448.70 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · nonDerivative · entry 4 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 13,810 | $67.81 | $936,456.10 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 224 | $67.81 | $15,189.44 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| April 30, 2020 Filed Jul 16, 2020 01:32 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 339 | $62.59 | $21,216.65 |
DisclosureSEC source: 0001567619-20-013325 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,995 F1 · date: Represents shares acquired by the reporting person on April 30, 2020, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 18:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,680 | $97.32 | $260,813.31 |
DisclosureSEC source: 0001567619-20-008539 · doc1.xml · nonDerivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,656 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $97.17 to $97.50. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 18:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,678 | $96.85 | $356,211.36 |
DisclosureSEC source: 0001567619-20-008539 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,336 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $96.17 to $97.15. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 24, 2020 Filed Apr 28, 2020 18:37 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 13,642 | $95.34 | $1,300,592.81 |
DisclosureSEC source: 0001567619-20-008539 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,014 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. F2 · price: The price in column 4 is the weighted average price. The price actually received ranged from $95.015 to $95.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 21:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 17,213 | $90.00 | $1,549,170.00 |
DisclosureSEC source: 0001567619-20-008272 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,656 F1 · date: Trade made pursuant to a 10b5-1 plan executed on March 11, 2020. Read SEC document |
| March 20, 2020 Filed Mar 25, 2020 00:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,836 | $73.05 | $426,319.80 |
DisclosureSEC source: 0001567619-20-006968 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,869 Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 51,970 | $0.00 Strike: $73.82 | $0.00 |
DisclosureSEC source: 0001567619-20-006632 · doc1.xml · derivative · entry 3 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,970 Underlying: Common Stock · 51,970 shares Expires 2030-03-15 F2 · date: Option grant vests 12/48th on March 16, 2021 and 1/48th on the 16th day of each month thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 01:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 18,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-006632 · doc1.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,705 F1 · price: Restricted stock units granted on March 16, 2020. Price not applicable. Read SEC document |
| March 13, 2020 Filed Mar 18, 2020 01:15 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 10,496 | $84.50 | $886,912.00 |
DisclosureSEC source: 0001567619-20-006632 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,485 Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 02:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 13,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-005681 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,981 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2019 as set forth in the Issuer's audited financial statements. F3 · shares: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2020, 2021 and 2022, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:28 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon Qualified Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $113.20 | $0.00 |
DisclosureSEC source: 0001214659-20-000193 · marketforms-47235.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-01-02 F2 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 20:28 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-20-000193 · marketforms-47235.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 6,583 | Not disclosed Strike: $52.41 | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · derivative · entry 7 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,583 shares Expires 2029-06-14 F7 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $51.72 | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · derivative · entry 6 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F6 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $31.53 | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · derivative · entry 5 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-16 F5 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $26.18 | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · derivative · entry 4 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-10 F4 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $26.01 | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · derivative · entry 3 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-12 F3 · price: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,981 and 2,751 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerCommon Stock | 955 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · nonDerivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| November 08, 2019 Filed Nov 14, 2019 21:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Disposition to issuerCommon Stock | 6,878 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-056644 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 955 F1 · price: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $189,150 and 3,098 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 20:05 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 185 | $67.28 | $12,446.80 |
DisclosureSEC source: 0001209191-19-052461 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,833 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. F2 · balance_after: Includes 955 restricted stock units (RSUs) awarded on June 14, 2019 which vest in full on the first anniversary date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the RSUs become fully vested in the event of a change in control of the Company. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:49 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 212 | $58.86 | $12,478.32 |
DisclosureSEC source: 0001209191-19-041247 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,648 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. F2 · balance_after: Includes 955 restricted stock units (RSUs) awarded on June 14, 2019 which vest in full on the first anniversary date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the RSUs become fully vested in the event of a change in control of the Company. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 17:57 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantDirector Stock Option (right to buy) · Derivative | 6,583 | $0.00 Strike: $52.41 | $0.00 |
DisclosureSEC source: 0001209191-19-037781 · doc4.xml · derivative · entry 2 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,583 Underlying: Common Stock · 6,583 shares Expires 2029-06-14 F2 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the options become fully vested in the event of a change in control of the Company. Read SEC document |
| June 14, 2019 Filed Jun 18, 2019 17:57 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 955 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-037781 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,436 F1 · shares: Restricted stock units (RSUs) awarded on June 14, 2019 which vest in full on the first anniversary date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the RSUs become fully vested in the event of a change in control of the Company. Read SEC document |
| April 30, 2019 Filed Jun 7, 2019 22:52 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 309 | $68.78 | $21,253.64 |
DisclosureSEC source: 0001567619-19-013095 · doc1.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · President, Worldwide R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,845 F1 · date: Represents shares acquired by the reporting person on April 30, 2019 pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:01 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 149 | $66.84 | $9,959.16 |
DisclosureSEC source: 0001209191-19-023406 · doc4.xml · nonDerivative · entry 1 FUCHS HENRY J · CIK 0001197355 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,481 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.